Loading…
Underlying
Underlying Price
$6.01
Type
Put
Strike
9.5
Expiration
Dec 31, 2026
DTE
48d
Moneyness
ITM
Intrinsic
$3.49
IBRX 9.5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $1.42 | +10.94% | 6 | 44 |
| Nov 20, 2026 | 7d | $1.70 | -6.08% | 4 | 2 |
| Nov 27, 2026 | 14d | $2.10 | +3.96% | 15 | 11 |
| Dec 4, 2026 | 21d | $2.25 | +0.00% | 8 | 8 |
| Dec 11, 2026 | 28d | $2.00 | +0.00% | 19 | 24 |
| Dec 24, 2026 | 41d | — | — | 0 | 0 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.